Navigation Links
Development of novel therapies for endothelial damage may heal atherosclerotic plaques
Date:4/21/2013

BOSTON Heart disease and approximately half of all strokes are the results of advanced atherosclerosis with damaged endothelium, the inner lining of blood vessels. In 2009, the direct and indirect annual cost of heart disease and stroke was approximately $312.6 billion. Projections are for the total cost of heart disease to increase from $523 to $1.126 billion from 2013 to 2030. And by 2030, it is expected that there will be more than 148 million of the US population would have heart disease. Development of new technologies for assessing and treating endothelium damage will help reduce that financial burden as reduce the human health burden resulting from atherosclerosis.

Dr. Hua Pan, Research Instructor in Medicine at Dr. Samuel Wickline's Laboratory in Washington University School of Medicine, investigated quantitative evaluation and developed novel therapies for endothelial barrier damage. The evolution and severity of endothelium damage in advanced atherosclerotic plaque remain unknown, in part because quantifiable methods are lacking for its in vivo assessment. Her latest study is the first to demonstrate, in a well-established atherosclerosis mouse model, ApoE deficient mice, a multifunctional perfluorocarbon (PFC) nanoparticle (NP) for quantification of endothelial damage as well as targeted anti-inflammatory drug delivery to the endothelium damage site.

The study, conducted in ApoE deficient mice, quantified endothelium damage by using PFC NP retained in mouse aorta as surrogate. It demonstrated the evolution and severity of endothelium damage in correlation to the length of the animal fat-diet consumption. Moreover, the same PFC NP loaded with anti-inflammatory drug, NF-κB inhibitor, down-regulated inflammation. Dr. Wickline noted, this finding provided a new avenue for defining disease stage and for following therapy to heal dangerous atherosclerotic plaques.

Her findings will be presented April 22, 2013 during Experimental Biology 2013 in Boston, MA.


'/>"/>

Contact: Jim Bernstein
jbernstein@aspet.org
301-646-3259
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Artificial womb unlocks secrets of early embryo development
2. REST is crucial for the timing of brain development
3. Embryonic development protein active in cancer growth
4. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
5. Stomata development in plants unraveled -- a valuable discovery for environmental research
6. Promising developments in early diagnosis and treatment of mesothelioma
7. Europe meets to discuss progress in energy research and development
8. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
9. New genes contributing to autism and related neurodevelopmental disorders uncovered
10. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
11. Navigating the IP Minefield of Human Embryonic Stem Cell Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... Research and Markets has announced the addition of the ... their offering. ... The global bioinformatics market ... 6.21 Billion in 2016, growing at a CAGR of 21.1% during ... is driven by the growing demand for nucleic acid and protein ...
(Date:11/14/2016)... Nov. 14, 2016  Based on its ... Frost & Sullivan recognizes FST Biometrics with ... for Visionary Innovation Leadership. FST Biometrics emerged ... identification market by pioneering In Motion Identification ... instant, seamless, and non-invasive verification. This patented ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... DENVER, COLORADO (PRWEB) , ... December 05, 2016 ... ... podcast series hosted by one of the nation’s premier cannabis technology and application ... the founder and CEO of Cultivate Colorado. Over the past 30 years, Chip ...
(Date:12/5/2016)... , Dec. 5, 2016  Renova™ Therapeutics, a ... heart failure and other chronic diseases, announced that ... company as Chief Financial Officer (CFO), effective today. ... 20 years of experience in financial management for ... and software companies. Most recently, Ms. Bovenizer was ...
(Date:12/5/2016)... LAKE, N.J. , Dec. 5, 2016 /PRNewswire/ ... Phase 3 open-label two-year study of rufinamide, which ... the American Epilepsy Society (AES) held from December ... Analysis of final two-year safety, tolerability and cognitive ... with rufinamide experienced similar safety and tolerability profiles, ...
(Date:12/4/2016)... ... December 02, 2016 , ... A proposed five-year ... in federally funded research and development is welcome news for the photonics community, ... . , As part of the National Defense Authorization Act (NDAA) compromise agreement ...
Breaking Biology Technology: